HIV Antivirals Industry Research Report 2025
Description
Summary
According to APO Research, the global HIV Antivirals market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for HIV Antivirals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for HIV Antivirals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for HIV Antivirals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of HIV Antivirals include Teva Pharmaceuticals, Merck & Co., Roche, Gilead Sciences, AbbVie, ViiV Healthcare, Johnson & Johnson (Janssen Pharmaceuticals) and Bristol-Myers Squibb, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for HIV Antivirals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HIV Antivirals.
The report will help the HIV Antivirals manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The HIV Antivirals market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global HIV Antivirals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
HIV Antivirals Segment by Company
Teva Pharmaceuticals
Merck & Co.
Roche
Gilead Sciences
AbbVie
ViiV Healthcare
Johnson & Johnson (Janssen Pharmaceuticals)
Bristol-Myers Squibb
HIV Antivirals Segment by Type
Protease Inhibitors (Pls)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
Fixed Dose Combinations (FDCs)
Nucleoside Reverse Transcriptase lnhibitors (NRTls)
Entry Inhibitors -CCR5 co-receptor antagonist
Integrase Strand Transfer Inhibitors (lNSTls)
Others
HIV Antivirals Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
HIV Antivirals Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Antivirals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of HIV Antivirals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Antivirals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of HIV Antivirals manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of HIV Antivirals by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of HIV Antivirals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global HIV Antivirals market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for HIV Antivirals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for HIV Antivirals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for HIV Antivirals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of HIV Antivirals include Teva Pharmaceuticals, Merck & Co., Roche, Gilead Sciences, AbbVie, ViiV Healthcare, Johnson & Johnson (Janssen Pharmaceuticals) and Bristol-Myers Squibb, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for HIV Antivirals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HIV Antivirals.
The report will help the HIV Antivirals manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The HIV Antivirals market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global HIV Antivirals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
HIV Antivirals Segment by Company
Teva Pharmaceuticals
Merck & Co.
Roche
Gilead Sciences
AbbVie
ViiV Healthcare
Johnson & Johnson (Janssen Pharmaceuticals)
Bristol-Myers Squibb
HIV Antivirals Segment by Type
Protease Inhibitors (Pls)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
Fixed Dose Combinations (FDCs)
Nucleoside Reverse Transcriptase lnhibitors (NRTls)
Entry Inhibitors -CCR5 co-receptor antagonist
Integrase Strand Transfer Inhibitors (lNSTls)
Others
HIV Antivirals Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
HIV Antivirals Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Antivirals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of HIV Antivirals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Antivirals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of HIV Antivirals manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of HIV Antivirals by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of HIV Antivirals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
120 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global HIV Antivirals Market Size (2020-2031)
- 2.2.2 Global HIV Antivirals Sales (2020-2031)
- 2.2.3 Global HIV Antivirals Market Average Price (2020-2031)
- 2.3 HIV Antivirals by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 Protease Inhibitors (Pls)
- 2.3.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls)
- 2.3.4 Fixed Dose Combinations (FDCs)
- 2.3.5 Nucleoside Reverse Transcriptase lnhibitors (NRTls)
- 2.3.6 Entry Inhibitors -CCR5 co-receptor antagonist
- 2.3.7 Integrase Strand Transfer Inhibitors (lNSTls)
- 2.3.8 Others
- 2.4 HIV Antivirals by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Hospital Pharmacies
- 2.4.3 Retail Pharmacies
- 2.4.4 Online Pharmacies
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global HIV Antivirals Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global HIV Antivirals Sales (K Units) of Manufacturers (2020-2025)
- 3.3 Global HIV Antivirals Revenue of Manufacturers (2020-2025)
- 3.4 Global HIV Antivirals Average Price by Manufacturers (2020-2025)
- 3.5 Global HIV Antivirals Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of HIV Antivirals, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of HIV Antivirals, Product Type & Application
- 3.8 Global Manufacturers of HIV Antivirals, Established Date
- 3.9 Global HIV Antivirals Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Teva Pharmaceuticals
- 4.1.1 Teva Pharmaceuticals Company Information
- 4.1.2 Teva Pharmaceuticals Business Overview
- 4.1.3 Teva Pharmaceuticals HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Teva Pharmaceuticals HIV Antivirals Product Portfolio
- 4.1.5 Teva Pharmaceuticals Recent Developments
- 4.2 Merck & Co.
- 4.2.1 Merck & Co. Company Information
- 4.2.2 Merck & Co. Business Overview
- 4.2.3 Merck & Co. HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Merck & Co. HIV Antivirals Product Portfolio
- 4.2.5 Merck & Co. Recent Developments
- 4.3 Roche
- 4.3.1 Roche Company Information
- 4.3.2 Roche Business Overview
- 4.3.3 Roche HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Roche HIV Antivirals Product Portfolio
- 4.3.5 Roche Recent Developments
- 4.4 Gilead Sciences
- 4.4.1 Gilead Sciences Company Information
- 4.4.2 Gilead Sciences Business Overview
- 4.4.3 Gilead Sciences HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Gilead Sciences HIV Antivirals Product Portfolio
- 4.4.5 Gilead Sciences Recent Developments
- 4.5 AbbVie
- 4.5.1 AbbVie Company Information
- 4.5.2 AbbVie Business Overview
- 4.5.3 AbbVie HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 AbbVie HIV Antivirals Product Portfolio
- 4.5.5 AbbVie Recent Developments
- 4.6 ViiV Healthcare
- 4.6.1 ViiV Healthcare Company Information
- 4.6.2 ViiV Healthcare Business Overview
- 4.6.3 ViiV Healthcare HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 ViiV Healthcare HIV Antivirals Product Portfolio
- 4.6.5 ViiV Healthcare Recent Developments
- 4.7 Johnson & Johnson (Janssen Pharmaceuticals)
- 4.7.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Information
- 4.7.2 Johnson & Johnson (Janssen Pharmaceuticals) Business Overview
- 4.7.3 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 Johnson & Johnson (Janssen Pharmaceuticals) HIV Antivirals Product Portfolio
- 4.7.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Developments
- 4.8 Bristol-Myers Squibb
- 4.8.1 Bristol-Myers Squibb Company Information
- 4.8.2 Bristol-Myers Squibb Business Overview
- 4.8.3 Bristol-Myers Squibb HIV Antivirals Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Bristol-Myers Squibb HIV Antivirals Product Portfolio
- 4.8.5 Bristol-Myers Squibb Recent Developments
- 5 Global HIV Antivirals Market Scenario by Region
- 5.1 Global HIV Antivirals Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global HIV Antivirals Sales by Region: 2020-2031
- 5.2.1 Global HIV Antivirals Sales by Region: 2020-2025
- 5.2.2 Global HIV Antivirals Sales by Region: 2026-2031
- 5.3 Global HIV Antivirals Revenue by Region: 2020-2031
- 5.3.1 Global HIV Antivirals Revenue by Region: 2020-2025
- 5.3.2 Global HIV Antivirals Revenue by Region: 2026-2031
- 5.4 North America HIV Antivirals Market Facts & Figures by Country
- 5.4.1 North America HIV Antivirals Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America HIV Antivirals Sales by Country (2020-2031)
- 5.4.3 North America HIV Antivirals Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe HIV Antivirals Market Facts & Figures by Country
- 5.5.1 Europe HIV Antivirals Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe HIV Antivirals Sales by Country (2020-2031)
- 5.5.3 Europe HIV Antivirals Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific HIV Antivirals Market Facts & Figures by Country
- 5.6.1 Asia Pacific HIV Antivirals Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific HIV Antivirals Sales by Country (2020-2031)
- 5.6.3 Asia Pacific HIV Antivirals Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America HIV Antivirals Market Facts & Figures by Country
- 5.7.1 South America HIV Antivirals Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America HIV Antivirals Sales by Country (2020-2031)
- 5.7.3 South America HIV Antivirals Revenue by Country (2020-2031)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa HIV Antivirals Market Facts & Figures by Country
- 5.8.1 Middle East and Africa HIV Antivirals Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa HIV Antivirals Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa HIV Antivirals Revenue by Country (2020-2031)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
- 6 Segment by Type
- 6.1 Global HIV Antivirals Sales by Type (2020-2031)
- 6.1.1 Global HIV Antivirals Sales by Type (2020-2031) & (K Units)
- 6.1.2 Global HIV Antivirals Sales Market Share by Type (2020-2031)
- 6.2 Global HIV Antivirals Revenue by Type (2020-2031)
- 6.2.1 Global HIV Antivirals Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global HIV Antivirals Revenue Market Share by Type (2020-2031)
- 6.3 Global HIV Antivirals Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global HIV Antivirals Sales by Application (2020-2031)
- 7.1.1 Global HIV Antivirals Sales by Application (2020-2031) & (K Units)
- 7.1.2 Global HIV Antivirals Sales Market Share by Application (2020-2031)
- 7.2 Global HIV Antivirals Revenue by Application (2020-2031)
- 7.2.1 Global HIV Antivirals Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global HIV Antivirals Revenue Market Share by Application (2020-2031)
- 7.3 Global HIV Antivirals Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 HIV Antivirals Value Chain Analysis
- 8.1.1 HIV Antivirals Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 HIV Antivirals Production Mode & Process
- 8.2 HIV Antivirals Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 HIV Antivirals Distributors
- 8.2.3 HIV Antivirals Customers
- 9 Global HIV Antivirals Analyzing Market Dynamics
- 9.1 HIV Antivirals Industry Trends
- 9.2 HIV Antivirals Industry Drivers
- 9.3 HIV Antivirals Industry Opportunities and Challenges
- 9.4 HIV Antivirals Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
